Allena Pharmaceuticals (NASDAQ:ALNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. “

ALNA has been the subject of a number of other research reports. Wedbush reissued a “buy” rating and issued a $36.00 price target on shares of Allena Pharmaceuticals in a report on Tuesday, July 2nd. Credit Suisse Group began coverage on shares of LTC Properties in a report on Wednesday, July 10th. They issued an “underperform” rating and a $19.00 price target for the company. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $21.33.

Shares of Allena Pharmaceuticals stock traded up $0.27 during midday trading on Tuesday, reaching $4.39. The company had a trading volume of 4,270 shares, compared to its average volume of 113,484. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.24. The firm has a market cap of $85.43 million, a P/E ratio of -2.55 and a beta of 1.99. The company’s fifty day moving average is $4.59. Allena Pharmaceuticals has a 1-year low of $3.83 and a 1-year high of $12.38.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). Equities research analysts expect that Allena Pharmaceuticals will post -2.04 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALNA. Sphera Funds Management LTD. boosted its position in shares of Allena Pharmaceuticals by 24.9% during the first quarter. Sphera Funds Management LTD. now owns 431,193 shares of the company’s stock worth $3,027,000 after purchasing an additional 85,994 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Allena Pharmaceuticals by 8.2% during the fourth quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock worth $151,000 after purchasing an additional 2,118 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Allena Pharmaceuticals by 3.8% during the fourth quarter. Squarepoint Ops LLC now owns 43,500 shares of the company’s stock worth $237,000 after purchasing an additional 1,600 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Allena Pharmaceuticals by 8.1% during the fourth quarter. Geode Capital Management LLC now owns 72,314 shares of the company’s stock worth $394,000 after purchasing an additional 5,444 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Allena Pharmaceuticals by 0.8% during the fourth quarter. BlackRock Inc. now owns 581,971 shares of the company’s stock worth $3,172,000 after purchasing an additional 4,528 shares in the last quarter. 79.71% of the stock is owned by hedge funds and other institutional investors.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Story: Gap Up Stocks

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.